AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17090809 — intervention group
Group type: COMPARATOR
Intervention: Attention control counseling
Number of subjects: 165
Study 15159134 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian extract (600, 1200, and 1800 mg)
Number of subjects: 10
Study 15159134 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (10 mg)
Number of subjects: 10
Study 15159134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11319170 — intervention group
Group type: EXPERIMENTAL
Intervention: 13‐cis‐retinoic acid (13‐cRA)
Number of subjects: 86
Study 11319170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 9222733 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily in the morning
Number of subjects: 12
Study 9222733 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 40 mg once daily in the evening
Number of subjects: 12
Study 8203443 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling Foley catheter for 24 hours
Number of subjects: 100
Study 8203443 — intervention group
Group type: COMPARATOR
Intervention: No catheter
Number of subjects: 100
Study 3584298 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit Reversal (HR)
Number of subjects: 30
Study 3584298 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential Reinforcement of Other Behaviour (DRO)
Number of subjects: 30
Study 3584298 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 30
Study 29260291 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone calls (PC)
Number of subjects: 119
Study 29260291 — intervention group
Group type: COMPARATOR
Intervention: No phone calls (no PC)
Number of subjects: 119
Study 29260291 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate persistence after 1 year
Number of subjects: 119
Study 28725977 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (60,000 IU orally, weekly for 4 weeks) and calcium supplements (500 to 1,000 mg/day for 3 months)
Number of subjects: 43
Study 28725977 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 and calcium supplementation
Number of subjects: 43
Study 25222850 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counselling for parents
Number of subjects: 512
Study 25222850 — intervention group
Group type: COMPARATOR
Intervention: Standard self-help brochure (Control)
Number of subjects: 512
Study 25222850 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged abstinence
Number of subjects: 512
Study 23279924 — intervention group
Group type: EXPERIMENTAL
Intervention: Past 30‐day daily average number of cigarettes smoked
Number of subjects: 131
Study 23279924 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco dependence screener (TDS) in buprenorphine condition
Number of subjects: 131
Study 23279924 — intervention group
Group type: COMPARATOR
Intervention: Tobacco dependence screener (TDS) in methadone condition
Number of subjects: 131
Study 21991566 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative treatment with FPANS 100 μg q.i.d.
Number of subjects: 35
Study 21991566 — intervention group
Group type: COMPARATOR
Intervention: Not treated post-operatively with topical glucocorticoids
Number of subjects: 35
Study 17192770 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg rifampin (intravenous 30-min infusion)
Number of subjects: 11
Study 14704836 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet (250 mmol)
Number of subjects: 41
Study 14704836 — intervention group
Group type: COMPARATOR
Intervention: Low sodium diet (20 mmol)
Number of subjects: 41
Study 11641511 — intervention group
Group type: EXPERIMENTAL
Intervention: IL1B/IL1RN haplotypes
Number of subjects: 590
Study 9840896 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucket-handle tears (group B, n = 12)
Number of subjects: 35
Study 9840896 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap tears (group F, n = 15)
Number of subjects: 35
Study 9840896 — intervention group
Group type: EXPERIMENTAL
Intervention: Degenerative tears (group D, n = 8)
Number of subjects: 35
Study 9840896 — intervention group
Group type: COMPARATOR
Intervention: All groups (n = 35)
Number of subjects: 35
Study 8084699 — intervention group
Group type: EXPERIMENTAL
Intervention: Random group (2 additional batting-practice sessions each week for 6 weeks, 12 sessions total)
Number of subjects: 30
Study 8084699 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked group (2 additional batting-practice sessions each week for 6 weeks, 12 sessions total)
Number of subjects: 30
Study 8084699 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional practice)
Number of subjects: 30
Study 2737307 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose single agent cisplatinum (19 patients)
Number of subjects: 120
Study 2737307 — intervention group
Group type: EXPERIMENTAL
Intervention: Total abdominal and pelvic irradiation (3 patients)
Number of subjects: 120
Study 2737307 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative second-look laparotomy
Number of subjects: 120
Study 30597021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg every 8 hours (q8h)
Number of subjects: 2192
Study 30597021 — intervention group
Group type: COMPARATOR
Intervention: Ceftaroline fosamil 600 mg every 12 hours (q12h)
Number of subjects: 2192
Study 30646391 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg THC (smoked)
Number of subjects: 17
Study 30646391 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg THC (vaporized)
Number of subjects: 17
Study 30646391 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg THC (smoked)
Number of subjects: 17
Study 30646391 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg THC (vaporized)
Number of subjects: 17
Study 27500873 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (up to 600 mg a day for six days)
Number of subjects: 34
Study 27500873 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (up to 600 micrograms a day)
Number of subjects: 34
Study 24812898 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medical enema for brain resuscitation, relieving rigidity of muscles and activating collaterals for 14 days, alongside comprehensive rehabilitation training and intravenous Monosialotetrahexosylganglioside Sodium Injection for 10 days
Number of subjects: 111
Study 24812898 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive rehabilitation training and intravenous Monosialotetrahexosylganglioside Sodium Injection for 10 days
Number of subjects: 111
Study 24812898 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment and control groups
Number of subjects: 111
Study 23176129 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg of calcium carbonate combined with 400 IU of vitamin D(3)
Number of subjects: 4143
Study 23176129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4143
Study 20079704 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at first live birth <25 years and >or=3 pregnancies
Number of subjects: 1357
Study 20079704 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal status
Number of subjects: 1357
Study 17091486 — intervention group
Group type: EXPERIMENTAL
Intervention: VDC/IE
Number of subjects: 388
Study 17091486 — intervention group
Group type: COMPARATOR
Intervention: IRS-IV
Number of subjects: 388
Study 16364108 — intervention group
Group type: EXPERIMENTAL
Intervention: Original PEDro scale guidelines
Number of subjects: 140
Study 16364108 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised PEDro scale guidelines
Number of subjects: 140
Study 16364108 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised definitions for 'less than 15% dropout' and 'point measures and variability'
Number of subjects: 140
Study 16364108 — intervention group
Group type: EXPERIMENTAL
Intervention: PEDro scale items
Number of subjects: 140
Study 12544314 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin (1 to 5 mg daily for 14 weeks)
Number of subjects: 100
Study 12544314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 10817352 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoendocrine therapy followed by surgery
Number of subjects: 283
Study 10817352 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemoendocrine treatment after primary surgery
Number of subjects: 283
Study 10817352 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoendocrine therapy
Number of subjects: 283
Study 8639721 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival curves presentation
Number of subjects: 236
Study 8639721 — intervention group
Group type: EXPERIMENTAL
Intervention: Point estimates presentation
Number of subjects: 236
Study 1519498 — intervention group
Group type: EXPERIMENTAL
Intervention: MLCu375 IUD
Number of subjects: 1536
Study 1519498 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu220C IUD
Number of subjects: 1536
Study 1519498 — intervention group
Group type: COMPARATOR
Intervention: Stainless Steel Ring
Number of subjects: 1536
Study 1519498 — intervention group
Group type: COMPARATOR
Intervention: Uterine Cavity‐Shaped Device
Number of subjects: 1536
Study 6825540 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulated pancreatic enzyme preparation (Pankreon)
Number of subjects: 19
Study 6825540 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 19
Study 31340899 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological preparation
Number of subjects: 118
Study 31340899 — intervention group
Group type: COMPARATOR
Intervention: Control group (basic preparation)
Number of subjects: 118
Study 30134990 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting intervention providing training in dialogic book-sharing, conducted weekly for 7 weeks.
Number of subjects: 12
Study 30134990 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention).
Number of subjects: 12
Study 26808860 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (5,000 IU per day)
Number of subjects: 0
Study 26808860 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (PG)
Number of subjects: 0
Study 24445955 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended caffeine treatment
Number of subjects: 95
Study 24445955 — intervention group
Group type: COMPARATOR
Intervention: Usual care (controls)
Number of subjects: 95
Study 22585223 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg moxifloxacin and 900 mg rifapentine twice weekly
Number of subjects: 0
Study 22585223 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg moxifloxacin and 1,200 mg rifapentine once weekly
Number of subjects: 0
Study 19188848 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (12-month moderate-to-vigorous exercise combining aerobic and muscle strength training)
Number of subjects: 189
Study 19188848 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 189
Study 17355800 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanyl infusion at 0.1 microg x kg(‐1) x min(‐1)
Number of subjects: 60
Study 17355800 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl bolus injection at 1.5 microg x kg(‐1)
Number of subjects: 60
Study 17355800 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanyl infusion
Number of subjects: 60
Study 17355800 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl bolus injection
Number of subjects: 60
Study 15833578 — intervention group
Group type: EXPERIMENTAL
Intervention: mecamylamine (10 mg)
Number of subjects: 16
Study 15833578 — intervention group
Group type: EXPERIMENTAL
Intervention: mecamylamine + denicotinized cigarettes
Number of subjects: 16
Study 15833578 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 11792331 — intervention group
Group type: EXPERIMENTAL
Intervention: Iridium-192 gamma radiation
Number of subjects: 685
Study 11792331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 685
Study 11792331 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma radiation
Number of subjects: 685
Study 10421597 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 1577
Study 10421597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1577
Study 7675578 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent videotape (high arousal)
Number of subjects: 0
Study 7675578 — intervention group
Group type: COMPARATOR
Intervention: Bird-nest-building videotape (low arousal)
Number of subjects: 0
Study 1683411 — intervention group
Group type: EXPERIMENTAL
Intervention: tertatolol 5 mg o.d.
Number of subjects: 20
Study 1683411 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 6123884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 30 micrograms/kg
Number of subjects: 32
Study 6123884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 50 micrograms/kg
Number of subjects: 32
Study 6123884 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin 5 micrograms/kg
Number of subjects: 32
Study 6123884 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin 10 micrograms/kg
Number of subjects: 32
Study 31420397 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced duration prophylaxis up to month +3 followed by immuno-guided prophylaxis using QuantiFERON-CMV technique up to month +12
Number of subjects: 150
Study 31420397 — intervention group
Group type: COMPARATOR
Intervention: Usual prophylaxis strategy up to month +6 followed by pre-emptive therapy up to month +12
Number of subjects: 150
Study 30066184 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoplastic aligners (clear transparent PET-G thermoplastic sheets)
Number of subjects: 30
Study 30066184 — intervention group
Group type: COMPARATOR
Intervention: Self-ligating fixed appliances with nickel-titanium archwires
Number of subjects: 30
Study 30066184 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 30
Study 26963896 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid intravenous rehydration (3 litres Hartman's solution over 6 hours) and ongoing midwifery telephone support
Number of subjects: 53
Study 26963896 — intervention group
Group type: COMPARATOR
Intervention: Routine in-patient care (control group)
Number of subjects: 53
Study 23298702 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (30-minute musical session with headset)
Number of subjects: 44
Study 23298702 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual setting of an intensive care unit)
Number of subjects: 44
Study 21466589 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment (0.1%)
Number of subjects: 40
Study 21466589 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 40
Study 21466589 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study 17643519 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 22
Study 17643519 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 22
Study 17074021 — intervention group
Group type: EXPERIMENTAL
Intervention: rebamipide (100 mg, t.i.d.)
Number of subjects: 81
Study 17074021 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 81
Study 14561278 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral creatine supplementation (5 g d(‐1) for six weeks)
Number of subjects: 45
Study 10636278 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 460
Study 9292483 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory-flow limitation during exercise
Number of subjects: 9
Study 9292483 — intervention group
Group type: COMPARATOR
Intervention: Normal exercise without expiratory-flow limitation
Number of subjects: 9
Study 1547080 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioscopy
Number of subjects: 110
Study 1547080 — intervention group
Group type: COMPARATOR
Intervention: Arteriography
Number of subjects: 110
Study 3518725 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine (SB-7505) for 10 days
Number of subjects: 42
Study 29798823 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic capsular release (ACR)
Number of subjects: 50
Study 29798823 — intervention group
Group type: COMPARATOR
Intervention: Hydrodilatation (HD)
Number of subjects: 50
Study 27472572 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 352
Study 27472572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 352
Study 27472572 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Dexamethasone and Ondansetron
Number of subjects: 352
Study 27472572 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 352
Study 27472572 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone, Ondansetron, Combination
Number of subjects: 352
Study 24149768 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (E; n = 12)
Number of subjects: 23
Study 24149768 — intervention group
Group type: COMPARATOR
Intervention: Control group (C; n = 11)
Number of subjects: 23
Study 22147661 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 59
Study 20932179 — intervention group
Group type: EXPERIMENTAL
Intervention: Household salt iodine content measurement
Number of subjects: 639
Study 20932179 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary iodine concentration measurement
Number of subjects: 639
Study 20932179 — intervention group
Group type: COMPARATOR
Intervention: Comparison of UIC between genders
Number of subjects: 639
Study 20932179 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily salt intake measurement
Number of subjects: 639
Study 20932179 — intervention group
Group type: EXPERIMENTAL
Intervention: UIC classification according to WHO/ICCIDD/UNICEF
Number of subjects: 639
Study 18390769 — intervention group
Group type: EXPERIMENTAL
Intervention: Men (intervention group)
Number of subjects: 34
Study 18390769 — intervention group
Group type: COMPARATOR
Intervention: Women (control group)
Number of subjects: 34
Study 18325757 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone-in-adhesive matrix patch (4.8 mg testosterone daily, 2 patches of 60 cm2 every 48 hours)
Number of subjects: 224
Study 18325757 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular testosterone enanthate injection (every 3 weeks)
Number of subjects: 224
Study 14706764 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta‐estradiol and gestodene
Number of subjects: 133
Study 14706764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 11216754 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexipafant 10 mg
Number of subjects: 150
Study 11216754 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexipafant 100 mg
Number of subjects: 150
Study 11216754 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 150
Study 9010144 — intervention group
Group type: EXPERIMENTAL
Intervention: Six months of oral anticoagulant therapy
Number of subjects: 227
Study 9010144 — intervention group
Group type: COMPARATOR
Intervention: Indefinite oral anticoagulant therapy
Number of subjects: 227
Study 7692778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7692778 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 9
Study 7692778 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 9
Study 7692778 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 9
Study 3321865 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin antagonist (1‐deamino‐2‐D‐Tyr(OEt)‐4‐Thr‐8‐Orn‐oxytocin) 10 micrograms/kg body weight
Number of subjects: 14
Study 3321865 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 14
Study 31553765 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone exposure at 120 ppb
Number of subjects: 87
Study 31553765 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone exposure at 70 ppb
Number of subjects: 87
Study 31553765 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (0 ppb)
Number of subjects: 87
Study 30397714 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge assessment of dental hygienists regarding systemic diseases and oral health
Number of subjects: 192
Study 30397714 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence and comfort in managing patients with systemic conditions
Number of subjects: 192
Study 30397714 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement on the need for dental hygienists to be prepared to manage medically compromised patients
Number of subjects: 192
Study 26955679 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiakangling Capsule (JC) combined with reduction of 131I (50-80 microCi per gram of thyroid tissue) taken for one month after 131I treatment.
Number of subjects: 387
Study 26955679 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiakangling Capsule (JC) combined with reduction of 131I.
Number of subjects: 387
Study 24555788 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at SP6
Number of subjects: 60
Study 24555788 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at GB39
Number of subjects: 60
Study 24555788 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonacupoint acupuncture
Number of subjects: 60
Study 24555788 — intervention group
Group type: COMPARATOR
Intervention: All groups (SP6, GB39, Nonacupoint)
Number of subjects: 60
Study 22895207 — intervention group
Group type: EXPERIMENTAL
Intervention: External cold and vibration stimulation via Buzzy
Number of subjects: 120
Study 22895207 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 120
Study 21073098 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Active Motion (EAM)
Number of subjects: 27
Study 21073098 — intervention group
Group type: COMPARATOR
Intervention: Early Passive Motion (EPM)
Number of subjects: 27
Study 21073098 — intervention group
Group type: COMPARATOR
Intervention: Immobilization
Number of subjects: 27
Study 18201433 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 12
Study 18201433 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 12